Evidence map›Paper›PMID 37577653›Full record

ArticlebioRxiv : the preprint server for biology2023

Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts.

Zoi E Sychev, Abderrahman Day, Hannah E Bergom, Gabrianne Larson, Atef Ali, Megan Ludwig, Ella Boytim, Ilsa Coleman, Eva Corey, Stephen R Plymate and 3 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Zoi E SychevDepartment of Pharmacology, University of Minnesota, Minneapolis, MN, University of Minnesota, Minneapolis, MN.
Abderrahman DayDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN.
Hannah E BergomDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN.
Gabrianne LarsonDepartment of Pharmacology, University of Minnesota, Minneapolis, MN, University of Minnesota, Minneapolis, MN.
Atef AliDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN.
Megan LudwigDepartment of Pharmacology, University of Minnesota, Minneapolis, MN, University of Minnesota, Minneapolis, MN.
Ella BoytimDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN.
Ilsa ColemanFred Hutchinson Cancer Center, Seattle, WA.
Eva CoreyDepart of Urology, University of Washington, Seattle, WA.
Stephen R PlymateDivision of gerontology and Geriatrics Medicine, University of Washington, Seattle, WA.
Peter S NelsonFred Hutchinson Cancer Center, Seattle, WA.
Justin H HwangDepartment of Medicine, University of Minnesota Masonic Cancer Center, Minneapolis, MN.
Justin M DrakeDepartment of Pharmacology, University of Minnesota, Minneapolis, MN, University of Minnesota, Minneapolis, MN.
University of Minnesota · USFred Hutch Cancer Center · USUniversity of Washington · US

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
Steroid Metabolism in Castration-Resistant Prostate CancerP01CA163227 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI PETER S NELSON · 2013 to 2026
$25.0M
RET Regulation and Targeting in Neuroendocrine Prostate CancerR01CA269801 · NCI · UNIVERSITY OF MINNESOTA · PI Justin Michael Drake · 2022 to 2026
$2.2M
NCI NIH HHS P01 CA163227NCI NIH HHS P50 CA097186NCI NIH HHS R01 CA269801
6 · The paper itself

Abstract

Resistance to androgen deprivation therapies leads to metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma (AdCa) origin that can transform to emergent aggressive variant prostate cancer (AVPC) which has neuroendocrine (NE)-like features. To this end, we used LuCaP patient-derived xenograft (PDX) tumors, clinically relevant models that reflects and retains key features of the tumor from advanced prostate cancer patients. Here we performed proteome and phosphoproteome characterization of 48 LuCaP PDX tumors and identified over 94,000 peptides and 9,700 phosphopeptides corresponding to 7,738 proteins. When we compared 15 NE versus 33 AdCa PDX samples, we identified 309 unique proteins and 476 unique phosphopeptides that were significantly altered and corresponded to proteins that are known to distinguish these two phenotypes. Assessment of protein and RNA concordance from these tumors revealed increased dissonance in transcriptionally regulated proteins in NE and metabolite interconversion enzymes in AdCa.

Identifiers

PMID37577653
PMCPMC10418188
OpenAlexW4385604459

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.